Tampa, FL – Dr. Daniel Sullivan, Associate Center Director for Clinical Investigations, at the H. Lee Moffitt Cancer Center & Research Institute has been awarded a $4.8 million contract by the National Institutes of Health to promote Phase II clinical trials. Dr. Chris Garrett, member of the Gastrointestinal Tumor Program is the co-principal investigator. The contract “Early Therapeutics Development with Phase II Emphasis,” opened January 1 and lasts through the end of December 2008 with a possibility of $3.2 million of more funding for an additional two years. Moffitt doctors in this study include Scott Antonia, Adil Daud, Jeffrey Lancet, Pamela Munster, George Simon, Andy Trotti, JungSun Choi, Doug Letson and Martin Silbiger.
The goal of the trials is to assess the response to a specific drug or drug combination for patients with the same cancer type and taking samples of the tumors or blood for correlative research studies. The first cancers being studied are acute myeloid leukemia, kidney and lung.
As principal investigator of this contract, Dr. Sullivan serves on the National Cancer Institute’s Investigational Drug Steering Committee. This committee provides input to the federal government and works to design better clinical trials.
Other institutions in the Southeast Phase II consortium include Lineberger Comprehensive Cancer Center at the University of North Carolina – Chapel Hill; Vanderbilt-Ingram Cancer Center at Vanderbilt University; Winship Cancer Institute at Emory University; and Massey Cancer Center at Virginia Commonwealth University.
In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.